Surgical Management of Gastric Cancer: New Insights and Future Prospectives

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 10 June 2024 | Viewed by 1341

Special Issue Editors


E-Mail
Guest Editor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Interests: minimally invasive surgery; foregut surgery; colorectal surgery

E-Mail
Guest Editor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Interests: upper GI surgery; pancreatic cancer; pancreatic cancer surgery

Special Issue Information

Dear Colleagues,

Surgery still represents the cornerstone of treatment for gastric cancer. During the last decades, the improvement of multimodal treatments and the promising results achieved with minimally invasive approaches have ameliorated oncological outcomes and surgery sustainability for patients. This topic aims to offer a comprehensive overview of recent technological applications, advances, challenges, and future perspectives concerning the surgical treatment of gastric cancer. We invite manuscripts that contain both reviews and original articles. Potential topics include, but are not limited to, laparoscopic gastrectomy, robotic gastrectomy, the endoscopic treatment of early gastric cancer, the use of new technological tools (i.e., fluorescence-guided surgery), minimally invasive approaches, and endoscopic approaches for the treatment of gastric surgery complications.

Dr. Claudio Fiorillo
Dr. Giuseppe Quero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • minimally invasive gastrectomy
  • endoscopy
  • robotic surgery
  • surgical management

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Other

16 pages, 1374 KiB  
Systematic Review
Short-Term Outcomes Analysis Comparing Open, Laparoscopic, Laparoscopic-Assisted, and Robotic Distal Gastrectomy for Locally Advanced Gastric Cancer: A Randomized Trials Network Analysis
by Michele Manara, Alberto Aiolfi, Andrea Sozzi, Matteo Calì, Federica Grasso, Emanuele Rausa, Gianluca Bonitta, Luigi Bonavina and Davide Bona
Cancers 2024, 16(9), 1620; https://doi.org/10.3390/cancers16091620 - 23 Apr 2024
Viewed by 233
Abstract
Background. Minimally invasive surgery for the treatment of locally advanced gastric cancer (AGC) is debated. The aim of this study was to execute a comprehensive assessment of principal surgical treatments for resectable distal gastric cancer. Methods. Systematic review and randomized controlled trials (RCTs) [...] Read more.
Background. Minimally invasive surgery for the treatment of locally advanced gastric cancer (AGC) is debated. The aim of this study was to execute a comprehensive assessment of principal surgical treatments for resectable distal gastric cancer. Methods. Systematic review and randomized controlled trials (RCTs) network meta-analysis. Open (Op-DG), laparoscopic-assisted (LapAs-DG), totally laparoscopic (Lap-DG), and robotic distal gastrectomy (Rob-DG) were compared. Pooled effect-size measures were the risk ratio (RR), the weighted mean difference (WMD), and the 95% credible intervals (CrIs). Results. Ten RCTs (3823 patients) were included. Overall, 1012 (26.5%) underwent Lap-DG, 902 (23.6%) LapAs-DG, 1768 (46.2%) Op-DG, and 141 (3.7%) Rob-DG. Anastomotic leak, severe complications (Clavien–Dindo > 3), and in-hospital mortality were comparable. No differences were observed for reoperation rate, pulmonary complications, postoperative bleeding requiring transfusion, surgical-site infection, cardiovascular complications, number of harvested lymph nodes, and tumor-free resection margins. Compared to Op-DG, Lap-DG and LapAs-DG showed a significantly reduced intraoperative blood loss with a trend toward shorter time to first flatus and reduced length of stay. Conclusions. LapAs-DG, Lap-DG, and Rob-DG performed in referral centers by dedicated surgeons have comparable short-term outcomes to Op-DG for locally AGC. Full article
Show Figures

Figure 1

13 pages, 1273 KiB  
Systematic Review
Long-Term Impact of D2 Lymphadenectomy during Gastrectomy for Cancer: Individual Patient Data Meta-Analysis and Restricted Mean Survival Time Estimation
by Alberto Aiolfi, Davide Bona, Gianluca Bonitta, Francesca Lombardo, Michele Manara, Andrea Sozzi, Diana Schlanger, Calin Popa, Marta Cavalli, Giampiero Campanelli, Antonio Biondi and Luigi Bonavina
Cancers 2024, 16(2), 424; https://doi.org/10.3390/cancers16020424 - 19 Jan 2024
Viewed by 825
Abstract
Background: Debate exists concerning the impact of D2 vs. D1 lymphadenectomy on long-term oncological outcomes after gastrectomy for cancer. Methods: PubMed, MEDLINE, Scopus, and Web of Science were searched and randomized controlled trials (RCTs) analyzing the effect of D2 vs. D1 on survival [...] Read more.
Background: Debate exists concerning the impact of D2 vs. D1 lymphadenectomy on long-term oncological outcomes after gastrectomy for cancer. Methods: PubMed, MEDLINE, Scopus, and Web of Science were searched and randomized controlled trials (RCTs) analyzing the effect of D2 vs. D1 on survival were included. Overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS) were assessed. Restricted mean survival time difference (RMSTD) and 95% confidence intervals (CI) were used as effect size measures. Results: Five RCTs (1653 patients) were included. Overall, 805 (48.7%) underwent D2 lymphadenectomy. The RMSTD OS analysis shows that at 60-month follow-up, D2 patients lived 1.8 months (95% CI −4.2, 0.7; p = 0.14) longer on average compared to D1 patients. Similarly, 60-month CSS (1.2 months, 95% CI −3.9, 5.7; p = 0.72) and DFS (0.8 months, 95% CI −1.7, 3.4; p = 0.53) tended to be improved for D2 vs. D1 lymphadenectomy. Conclusions: Compared to D1, D2 lymphadenectomy is associated with a clinical trend toward improved OS, CSS, and DFS at 60-month follow-up. Full article
Show Figures

Figure 1

Back to TopTop